What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed?  

And Ehsan Rahimy, MD, reviews findings from a retrospective analysis seeking to understand if continuous glucose monitoring could reduce the risk of NPDR progressing to more serious conditions. Listen in to learn what he and his colleagues found.